Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6916941 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(5 months ago) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7420069 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(5 months ago) | |
US6916941
(Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(8 days from now) | |
US7420069
(Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(8 days from now) |
Market Authorisation Date: 14 August, 2002
Treatment: NA
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic